Pfizer: Profile of Sasanlimab Was Generally Consistent With Reported Safety Profile of Pd-1 Inhibitors
輝瑞:Sasanlimab的特徵與已報告的PD-1抑制劑的安全特徵基本一致
Pfizer: Profile of Sasanlimab Was Generally Consistent With Reported Safety Profile of Pd-1 Inhibitors
輝瑞:Sasanlimab的特徵與已報告的PD-1抑制劑的安全特徵基本一致
使用瀏覽器的分享功能,分享給你的好友吧